The short version of Incretin hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-23 and is reviewed periodically as new material appears.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
=== Safety concerns and training related to children === Orthopaedic specialists used to recommend that children avoid weight training because the growth plates on their bones might be at risk. The rare reports of growth plate fractures in children who trained with weights occurred under inadequate supervision or improper form or excess weight. There have been no reports of injuries to growth plates in youth training programs that follow established guidelines. The position of the National Strength and Conditioning Association is that strength training is safe for children if properly designed and supervised. The effects of training on youth have been shown to depend on the methods of training being implemented. Studies from the Journal of Strength and Conditioning Research concluded that both Resistance Training and Plyometric training led to significant improvements in peak torque, peak rate of torque development, and jump performance. Plyometric training also showed a greater improvement in jump performance compared to Resistance training. Another study saw results that suggest that both high-load, low-repetition and moderate-load, high-repetition resistance training can be prescribed to improve muscular fitness in untrained adolescents, as well as the jump height had also increased. Both plyometrics exercise and resistance training tend to result in better adaptations in the short and long term. This can be attributed to the effect of neuromuscular development, as well as the principle that it comes faster for adolescents than muscular hypertrophy.
Natural holmium (67Ho) contains one observationally stable isotope, 165Ho. The known isotopes of holmium range from 140Ho to 175Ho. The primary decay mode before the stable 165Ho, is beta plus decay to dysprosium isotopes, and the primary mode after is beta minus decay to erbium isotopes. Among the synthetic radioactive isotopes the most stable is 163Ho with a half-life of 4,570 years, the next most stable is 166Ho having a half-life of 26.812 hours, and others are under 4 hours. The isomeric nuclide 166m1Ho, however, has a half-life of 1,133 years, much the longest of the meta states. Holmium-166 (ground state) has been studied for medical application.
==== Inhaled substances (pneumoconiosis) ==== Inorganic Silicosis Asbestosis Berylliosis Industrial printing chemicals (e.g. carbon black, ink mist) Organic Hypersensitivity pneumonitis (extrinsic allergic alveolitis), representing approximately 15% of cases of ILD.
==== Other ==== A defibrillator, an electric device connected to the heart and surgically inserted under the skin, may be recommended. This is particularly if there are any ongoing signs of heart failure, with a low left ventricular ejection fraction and a New York Heart Association grade II or III after 40 days of the infarction. Defibrillators detect potentially fatal arrhythmia and deliver an electrical shock to the person to depolarize a critical mass of the heart muscle.
Sources: en.wikipedia.org
The functionality of a given protein is heavily dependent on its structure. Proteins reach this structure through the process of protein folding, which is facilitated by a variety of intra- and inter-molecular bonds. While much of the folding is driven by the formation of hydrogen bonds, covalent bonding of cysteine residues into disulfide bridges imposes constraints that stabilize particular conformations while preventing others from forming. As the bond energy of a covalent disulfide bridge is higher than the energy of a coordinate bond or hydrophobic interaction, greater numbers of disulfide bridges lead to higher energies required for protein denaturation. Disulfide bonds often serve to stabilize protein structures in the more oxidizing conditions of the extracellular environment. Within the cytoplasm, disulfide bonds may instead be reduced (i.e. in -SH form) to their constituent cysteine residues by thioredoxins. Many important cellular enzymes use prosthetic groups ending with sulfhydryl (-SH) moieties to handle reactions involving acyl-containing biochemicals: two common examples from basic metabolism are coenzyme A and alpha-lipoic acid. Cysteine-related metabolites homocysteine and taurine are other sulfur-containing amino acids that are similar in structure, but not coded by DNA, and are not part of the primary structure of proteins, take part in various locations of mammalian physiology. Two of the 13 classical vitamins, biotin and thiamine, contain sulfur, and serve as cofactors to several enzymes.
A poll of Arab-Americans in May 2002 found that 20% had personally experienced discrimination since September 11. A July 2002 poll of Muslim Americans found that 48% believed their lives had changed for the worse since September 11, and 57% had experienced an act of bias or discrimination. Following the September 11 attacks, many Pakistani Americans identified themselves as Indians to avoid potential discrimination and obtain jobs. By May 2002, there were 488 complaints of employment discrimination reported to the U.S. Equal Employment Opportunity Commission (EEOC). 301 of those were complaints from people fired from their jobs. Similarly, by June 2002, the U.S. Department of Transportation (DOT) had investigated 111 September 11th-related complaints from airline passengers purporting that their religious or ethnic appearance caused them to be singled out at security screenings in addition to 31 complaints from people who alleged they were blocked from boarding airplanes on the same grounds.
== P == PAS – Positron annihilation spectroscopy Photoacoustic spectroscopy PAT or PACT – Photoacoustic tomography or photoacoustic computed tomography PAX – Photoemission of adsorbed xenon PC or PCS – Photocurrent spectroscopy Phase contrast microscopy PhD – Photoelectron diffraction PD – Photodesorption PDEIS – Potentiodynamic electrochemical impedance spectroscopy PDS – Photothermal deflection spectroscopy PED – Photoelectron diffraction PEELS – parallel electron energy loss spectroscopy PEEM – Photoemission electron microscopy (or photoelectron emission microscopy) PES – Photoelectron spectroscopy PINEM – photon-induced near-field electron microscopy PIGE – Particle (or proton) induced gamma-ray spectroscopy, see nuclear reaction analysis PIXE – Particle (or proton) induced X-ray spectroscopy PL – Photoluminescence Porosimetry Powder diffraction PTMS – Photothermal microspectroscopy PTS – Photothermal spectroscopy
=== Legal status === In April 2025, the European Medicines Agency (EMA) recommended the refusal of a marketing authorization for Winlevi, a medicine intended for treating acne vulgaris. The EMA noted that Winlevi is a new class of medicine that blocks receptors for androgens. However, there is a risk of the medicine suppressing the working of three organs: the hypothalamus and pituitary glands in the brain and adrenal glands. The suppression of these organs could lead to impaired growth and sexual maturation, which is a major concern in adolescents. Although the company presented data to show that the risk was low, the EMA considered that these data, as well as measures the company proposed to minimize the risk, were not sufficient to approve the medicine for people from 12 years of age to less than 18 years of age. In May 2025, Cassiopea requested a re-examination of the EMA's April 2025 opinion. In October 2025, EMA issued marketing authorization for Winlevi.
Artistic Achievement – Hellblade: Senua's Sacrifice Audio Achievement – Hellblade: Senua's Sacrifice Best Game – What Remains of Edith Finch British Game – Hellblade: Senua's Sacrifice Debut Game – Gorogoa Evolving Game – Overwatch Family – Super Mario Odyssey Game Beyond Entertainment – Hellblade: Senua's Sacrifice Game Design – Super Mario Odyssey Game Innovation – The Legend of Zelda: Breath of the Wild Mobile Game – Golf Clash Multiplayer – Divinity: Original Sin II Music – Cuphead Narrative – Night in the Woods Original Property – Horizon Zero Dawn Performer – Melina Juergens (as Senua, Hellblade: Senua's Sacrifice) Special Award: Nolan North
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.